vs
Amphastar Pharmaceuticals, Inc.（AMPH）与Doximity, Inc.（DOCS）财务数据对比。点击上方公司名可切换其他公司
Doximity, Inc.的季度营收约是Amphastar Pharmaceuticals, Inc.的1.0倍（$185.1M vs $183.1M），Doximity, Inc.净利率更高（33.3% vs 13.3%，领先19.9%），Doximity, Inc.同比增速更快（9.8% vs -1.8%），过去两年Doximity, Inc.的营收复合增速更高（25.2% vs 3.2%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
Doximity Inc成立于2010年，是面向医疗专业人士的线上社交服务平台，为平台会员提供精选医疗资讯、远程医疗工具，以及病例协作相关功能，助力医疗从业者高效交流信息、开展诊疗相关工作。
AMPH vs DOCS — 直观对比
营收规模更大
DOCS
是对方的1.0倍
$183.1M
营收增速更快
DOCS
高出11.6%
-1.8%
净利率更高
DOCS
高出19.9%
13.3%
两年增速更快
DOCS
近两年复合增速
3.2%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $185.1M |
| 净利润 | $24.4M | $61.6M |
| 毛利率 | 46.8% | 89.9% |
| 营业利润率 | 19.4% | 38.9% |
| 净利率 | 13.3% | 33.3% |
| 营收同比 | -1.8% | 9.8% |
| 净利润同比 | -35.7% | -18.1% |
| 每股收益（稀释后） | $0.51 | $0.31 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHDOCS
| Q4 25 | $183.1M | $185.1M | ||
| Q3 25 | $191.8M | $168.5M | ||
| Q2 25 | $174.4M | $145.9M | ||
| Q1 25 | $170.5M | $138.3M | ||
| Q4 24 | $186.5M | $168.6M | ||
| Q3 24 | $191.2M | $136.8M | ||
| Q2 24 | $182.4M | $126.7M | ||
| Q1 24 | $171.8M | $118.1M |
净利润AMPHDOCS
| Q4 25 | $24.4M | $61.6M | ||
| Q3 25 | $17.4M | $62.1M | ||
| Q2 25 | $31.0M | $53.3M | ||
| Q1 25 | $25.3M | $62.5M | ||
| Q4 24 | $38.0M | $75.2M | ||
| Q3 24 | $40.4M | $44.2M | ||
| Q2 24 | $37.9M | $41.4M | ||
| Q1 24 | $43.2M | $40.6M |
毛利率AMPHDOCS
| Q4 25 | 46.8% | 89.9% | ||
| Q3 25 | 51.4% | 90.3% | ||
| Q2 25 | 49.6% | 89.2% | ||
| Q1 25 | 50.0% | 89.5% | ||
| Q4 24 | 46.5% | 91.6% | ||
| Q3 24 | 53.3% | 90.0% | ||
| Q2 24 | 52.2% | 89.3% | ||
| Q1 24 | 52.4% | 89.4% |
营业利润率AMPHDOCS
| Q4 25 | 19.4% | 38.9% | ||
| Q3 25 | 13.2% | 37.8% | ||
| Q2 25 | 24.2% | 37.4% | ||
| Q1 25 | 21.9% | 35.2% | ||
| Q4 24 | 24.2% | 47.4% | ||
| Q3 24 | 29.8% | 38.8% | ||
| Q2 24 | 30.3% | 36.4% | ||
| Q1 24 | 27.9% | 35.5% |
净利率AMPHDOCS
| Q4 25 | 13.3% | 33.3% | ||
| Q3 25 | 9.0% | 36.8% | ||
| Q2 25 | 17.8% | 36.5% | ||
| Q1 25 | 14.8% | 45.2% | ||
| Q4 24 | 20.4% | 44.6% | ||
| Q3 24 | 21.1% | 32.3% | ||
| Q2 24 | 20.8% | 32.7% | ||
| Q1 24 | 25.1% | 34.4% |
每股收益（稀释后）AMPHDOCS
| Q4 25 | $0.51 | $0.31 | ||
| Q3 25 | $0.37 | $0.31 | ||
| Q2 25 | $0.64 | $0.27 | ||
| Q1 25 | $0.51 | $0.31 | ||
| Q4 24 | $0.74 | $0.37 | ||
| Q3 24 | $0.78 | $0.22 | ||
| Q2 24 | $0.73 | $0.21 | ||
| Q1 24 | $0.81 | $0.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $64.8M |
| 总债务越低越好 | $608.7M | — |
| 股东权益账面价值 | $788.8M | $979.3M |
| 总资产 | $1.6B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.77× | — |
8季度趋势，按日历期对齐
现金及短期投资AMPHDOCS
| Q4 25 | $282.8M | $64.8M | ||
| Q3 25 | $276.2M | $169.2M | ||
| Q2 25 | $231.8M | $137.3M | ||
| Q1 25 | $236.9M | $209.6M | ||
| Q4 24 | $221.6M | $165.3M | ||
| Q3 24 | $250.5M | $184.2M | ||
| Q2 24 | $217.8M | $111.4M | ||
| Q1 24 | $289.6M | $96.8M |
总债务AMPHDOCS
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
股东权益AMPHDOCS
| Q4 25 | $788.8M | $979.3M | ||
| Q3 25 | $776.7M | $1.1B | ||
| Q2 25 | $757.5M | $1.0B | ||
| Q1 25 | $751.3M | $1.1B | ||
| Q4 24 | $732.3M | $1.0B | ||
| Q3 24 | $727.7M | $961.2M | ||
| Q2 24 | $713.3M | $913.6M | ||
| Q1 24 | $672.4M | $901.4M |
总资产AMPHDOCS
| Q4 25 | $1.6B | $1.2B | ||
| Q3 25 | $1.7B | $1.3B | ||
| Q2 25 | $1.6B | $1.2B | ||
| Q1 25 | $1.6B | $1.3B | ||
| Q4 24 | $1.6B | $1.2B | ||
| Q3 24 | $1.5B | $1.1B | ||
| Q2 24 | $1.5B | $1.1B | ||
| Q1 24 | $1.6B | $1.1B |
负债/权益比AMPHDOCS
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $60.9M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | — |
| 自由现金流率自由现金流/营收 | 13.4% | — |
| 资本支出强度资本支出/营收 | 4.5% | — |
| 现金转化率经营现金流/净利润 | 1.35× | 0.99× |
| 过去12个月自由现金流最近4个季度 | $121.2M | — |
8季度趋势，按日历期对齐
经营现金流AMPHDOCS
| Q4 25 | $32.9M | $60.9M | ||
| Q3 25 | $52.6M | $93.9M | ||
| Q2 25 | $35.6M | $62.1M | ||
| Q1 25 | $35.1M | $98.5M | ||
| Q4 24 | $29.0M | $65.2M | ||
| Q3 24 | $60.0M | $68.3M | ||
| Q2 24 | $69.1M | $41.2M | ||
| Q1 24 | $55.3M | $63.9M |
自由现金流AMPHDOCS
| Q4 25 | $24.6M | — | ||
| Q3 25 | $47.2M | — | ||
| Q2 25 | $25.0M | — | ||
| Q1 25 | $24.4M | — | ||
| Q4 24 | $16.6M | — | ||
| Q3 24 | $46.2M | — | ||
| Q2 24 | $63.1M | — | ||
| Q1 24 | $46.5M | — |
自由现金流率AMPHDOCS
| Q4 25 | 13.4% | — | ||
| Q3 25 | 24.6% | — | ||
| Q2 25 | 14.3% | — | ||
| Q1 25 | 14.3% | — | ||
| Q4 24 | 8.9% | — | ||
| Q3 24 | 24.1% | — | ||
| Q2 24 | 34.6% | — | ||
| Q1 24 | 27.1% | — |
资本支出强度AMPHDOCS
| Q4 25 | 4.5% | — | ||
| Q3 25 | 2.8% | — | ||
| Q2 25 | 6.1% | — | ||
| Q1 25 | 6.3% | 0.0% | ||
| Q4 24 | 6.7% | 0.0% | ||
| Q3 24 | 7.2% | 0.0% | ||
| Q2 24 | 3.3% | 0.0% | ||
| Q1 24 | 5.1% | 0.0% |
现金转化率AMPHDOCS
| Q4 25 | 1.35× | 0.99× | ||
| Q3 25 | 3.03× | 1.51× | ||
| Q2 25 | 1.15× | 1.16× | ||
| Q1 25 | 1.39× | 1.58× | ||
| Q4 24 | 0.76× | 0.87× | ||
| Q3 24 | 1.48× | 1.55× | ||
| Q2 24 | 1.82× | 1.00× | ||
| Q1 24 | 1.28× | 1.57× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
DOCS
| Subscription | $175.4M | 95% |
| Service Other | $9.7M | 5% |
